In a closely watched move, a U.K. parliamentary committee is pressuring a pair of key U.K. government agencies and Vertex Pharmaceuticals (VRTX) to settle a long-running dispute over access to a pricey cystic fibrosis drug.

To wit, the Health and Social Care Committee has formally requested documents from the drug maker, the National Health Service in England, and the National Institute for Health and Care Excellence, which is an official cost-effectiveness watchdog, for paperwork that details bitter negotiations over the Orkambi medication. NICE had determined the drug was not worth what Vertex sought to charge.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy